Dipeptidyl peptidase‐4 inhibitor‐associated cutaneous eruptions: a retrospective observational study
- 20 February 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 47 (7) , 1283-1290
Abstract
Background: Dipeptidyl peptidase-4 (DPP-4) plays a complex role in immune regulation and its inhibition can have effects on the pathogenesis of various skin diseases. Studies have shown that DPP-4 inhibitors are associated with an increased risk of bullous pemphigoid. Objectives: To analyze the clinical and histopathological features of cutaneous adverse events in patients on DPP-4 inhibitors. Methods: We performed a retrospective review of patients with suspected DPP-4 inhibitor associated cutaneous adverse events, at a tertiary teaching hospital from 1st January 2017 to 31st December 2020. Patients with previous history of chronic skin disease, those without histopathological reports or follow-up records were excluded. The clinical characteristics, latency period, Naranjo adverse drug reaction probability scale and clinical outcomes were evaluated. Results: 18 patients (M:F-10:8) with a mean age of 68.6 years (range:38-89) were included. The distribution of DPP-4 inhibitors was Teneligliptin (N=6), Vildagliptin (N=6), Sitagliptin (N=4), Linagliptin (N=1) and Saxagliptin (N=1). The mean duration of onset of lesions after the initiation of therapy was 8.8 months (Range:1-24 months). Dermatoses noted were bullous pemphigoid (N=12, 66.6%), lichenoid dermatitis (N=4, 22.2%), psoriasiform dermatitis (N=1, 5.6%) and spongiotic dermatitis (N=1, 5.6%). 8 patients (44.4%) had necrotic keratinocytes as one of the distinct histological features. Causality assessment using the Naranjo adverse event scale place the causative role of DPP-4 inhibitors as ‘possible’ in all patients. 11 patients (61.1%) noted improvement in their condition following discontinuation of DPP-4 inhibitors, with 5 patients having complete remission within 6 months of stopping the drug. Conclusion: DPP-4 inhibitors associated dermatoses need not necessarily be limited to bullous pemphigoid. It is necessary to recognize the possibility of other dermatoses in patients on DPP-4 inhibitors as substitution of the drug may improve disease morbidity.Keywords
This publication has 18 references indexed in Scilit:
- Higher Frequency of Dipeptidyl Peptidase-4 Inhibitor Intake in Bullous Pemphigoid Patients than in the French General PopulationJournal of Investigative Dermatology, 2019
- Decrease in eosinophils infiltrating into the skin of patients with dipeptidyl peptidase‐4 inhibitor‐related bullous pemphigoidThe Journal of Dermatology, 2018
- Autoantibody Profile Differentiates between Inflammatory and Noninflammatory Bullous PemphigoidJournal of Investigative Dermatology, 2016
- Case of lichen planus induced by sitagliptin phosphate hydrateThe Journal of Dermatology, 2016
- Drug-induced skin reactions: a pathologist viewpointCutaneous and Ocular Toxicology, 2015
- Vascular Origin of Vildagliptin-induced Skin Effects in Cynomolgus MonkeysToxicologic Pathology, 2014
- Histopathological Patterns Indicative of Distinct Adverse Drug Reactions2012
- Persistent edematous-plaque photosensitivity observed with sitagliptin phosphate (Januvia®)Dermatology Online Journal, 2012
- Drug eruption caused by sitagliptin, a dipeptidyl peptidase‐IV inhibitorThe Journal of Dermatology, 2011
- Psoriasiform eruption triggered by a dipeptidyl peptidase IV inhibitorAustralasian Journal of Dermatology, 2011